Latest

DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well-characterized patient cohorts.…

David Pinato and Lung Yi Mak have been awarded the prestigious EASL Emerging Leader Award, recognizing their outstanding contributions to liver research. The award, presented annually at the EASL Congress, is dedicated…

Collaborating with multinational liver societies, patient advocacy groups, and leading experts and researchers, a global consortium will unveil a new nomenclature for the prevalent Non-Alcoholic Fatty Liver Disease (NAFLD) at the upcoming…

The A-TANGO consortium performs Phase 2 clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. This novel combinatorial therapy is called G-TAK. In addition, A-TANGO strives to…

MICROB-PREDICT aims to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to…

Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) funded by the European Innovative Medicines Initiative 2 Joint Undertaking, brings together clinicians and scientists from prominent academic centres across Europe with companies from…

EASL is pleased to announce the release of the EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma to coincide with the EASL Liver Cancer Summit 2023. Intrahepatic cholangiocarcinoma (iCCA) represents…